Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyDabigatran etexilate
Identification
- Name
- Dabigatran etexilate
- Accession Number
- DB06695
- Type
- Small Molecule
- Groups
- Approved
- Description
Dabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. FDA approved on October 19, 2010.
- Structure
Structure for DB06695 (Dabigatran etexilate)
- Synonyms
- Ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino] propanoate
- External IDs
- BIBR 1048 / BIBR 1048 BS RS1 / BIBR-1048 / BIBR-1048-BS-RS1
- Product Ingredients
Ingredient UNII CAS InChI Key Dabigatran etexilate mesilate SC7NUW5IIT 872728-81-9 XETBXHPXHHOLOE-UHFFFAOYSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Pradaxa Capsule 150 mg Oral Boehringer Ingelheim 2008-03-18 Not applicable EU 
Pradaxa Capsule 75 mg Oral Boehringer Ingelheim (Canada) Ltd Ltee 2008-07-03 Not applicable Canada 
Pradaxa Capsule 150 mg/1 Oral Rebel Distributors 2010-10-26 Not applicable US 
Pradaxa Capsule 110 mg Oral Boehringer Ingelheim 2008-03-18 Not applicable EU Pradaxa Capsule 150 mg Oral Boehringer Ingelheim 2008-03-18 Not applicable EU Pradaxa Capsule 75 mg Oral Boehringer Ingelheim 2008-03-18 Not applicable EU Pradaxa Capsule 150 mg Oral Boehringer Ingelheim 2008-03-18 Not applicable EU Pradaxa Capsule 110 mg Oral Boehringer Ingelheim 2008-03-18 Not applicable EU Pradaxa Capsule 150 mg Oral Boehringer Ingelheim 2008-03-18 Not applicable EU Pradaxa Capsule 110 mg/1 Oral Boehringer Ingelheim 2015-11-23 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-dabigatran Capsule 75 mg Oral Apotex Corporation Not applicable Not applicable Canada Apo-dabigatran Capsule 150 mg Oral Apotex Corporation Not applicable Not applicable Canada Apo-dabigatran Capsule 110 mg Oral Apotex Corporation Not applicable Not applicable Canada Teva-dabigatran Capsule 75 mg Oral Teva Not applicable Not applicable Canada Teva-dabigatran Capsule 150 mg Oral Teva Not applicable Not applicable Canada - International/Other Brands
- Pradax (Boehringer Ingelheim) / Rendix
- Categories
- UNII
- 2E18WX195X
- CAS number
- 211915-06-9
- Weight
- Average: 627.7332
Monoisotopic: 627.316917457 - Chemical Formula
- C34H41N7O5
- InChI Key
- KSGXQBZTULBEEQ-UHFFFAOYSA-N
- InChI
- InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)
- IUPAC Name
- ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate
- SMILES
- CCCCCCOC(=O)N=C(N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=CC=CC=N3)N2C)C=C1
Pharmacology
- Indication
Dabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials). In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial). Contraindications: severe renal impairment (CrCL < 30 ml/min); haemorrhagic manifestations, bleeding diathesis or spontaneous or pharmacologic impairment of haemostasis; lesions at risk of clinically significant bleeding (e.g. extensive cerebral infarction (haemorrhagic or ischemic) in the last 6 months, active peptic ulcer disease); concomitant treatment with P-glycoprotein inhibitors (e.g. oral ketoconazole, verapamil); and those with known hypersensitivity to dabigatran, dabigatran etexilate or any ingredient used in the formulation or component of the container. As of December 2012, dabigatran is contraindicated in patients with mechanical prosthetic heart valves.
- Associated Conditions
- Pharmacodynamics
Dabigatran directly inhibits thrombin in a concentration-dependent, reversible, specific, and competitive manner which results in a prolongation of aPTT (partial thromboplastin time), ECT (Ecarin clotting time), and TT (thrombin time). It may increase INR but this laboratory parameter is relatively insensitive to the activity of dabigatran.
- Mechanism of action
Dabigatran etexilate is an inactive pro-drug that is converted to dabigatran, the active form, by esterase-catalyzed hydrolysis in the plasma and liver. Dabigatran, the main active principle in plasma, is a rapid-acting competitive and reversible direct inhibitor of thrombin. Thrombin, a serine protease, is responsible for the conversion of fibrinogen to fibrin in the coagulation cascade. Inhibition of thrombin consequently prevents thrombus development. Dabigatran inhibits free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation.
Target Actions Organism AProthrombin inhibitorHuman - Absorption
Peak plasma concentrations were achieved in 6 hours in post surgical patients. In healthy patients, maximum concentrations were achieved in 0.5 to 2 hours. The absolute bioavailability of dabigatran in the body after administration of dabigatran etexilate was 6.5%. Food does not affect the bioavailability of dabigatran etexilate, but it delays the time to peak plasma concentrations by 2 hours. Oral bioavailability may increase by up to 75% when pellets are taken out of the hydroxypropylmethylcellulose (HPMC) capsule. Therefore, capsules should not be opened and pellets taken alone. Furthermore, although absorption of dabigatran etexilate is independent of gastrointestinal acidity, coadministration of pantoprazole (proton pump inhibitor) may reduce the bioavailability of dabigatran. Despite this finding, dose adjustment is not required.
- Volume of distribution
Moderate tissue distribution with a Vd of 60-70L. Accumulation factor, twice daily dosing = 2
- Protein binding
Relatively low binding (34-35%) to plasma proteins.
- Metabolism
CYP450 enzymes are not involved in the metabolism of dabigatran thus is not expected to interact with drugs metabolized by CYP isoenzymes. Dabigatran is typically metabolised by esterases and microsomal carboxylesterases. Pharmacologically active acylglucoronides are formed via conjugation. Four positional isomers, 1-O, 2-O, 3-O, and 4-O, acylglucuronides exist, each accounting for less than 10% of total plasma dabagatran.
- Route of elimination
Mainly excreted in urine (85%). Fecal excretion accounts for 6% of the orally administered dose. Dabigatran is primarily eliminated unchanged via the kidneys at a rate of 100 ml/min corresponding to the glomerular filtration rate.
- Half life
12-14 hours in healthy volunteers. 14-17 hours in patients treated for prevention of venous thromboembolism following hip- or knee-replacement surgery.
- Clearance
- Not Available
- Toxicity
The most common adverse reactions include dyspepsia or gastritis-like symptoms. The approximate lethal dose (LD50) in rats and mice was observed at single oral doses of > 2000 mg/kg. Oral doses of 600 mg/kg did not induce any toxicologically meaningful changes in dogs and Rhesus monkeys. Dabigatran was well-tolerated in rats and Rhesus monkeys during repeat-dose toxicity studies. No evidence of mutagenic potential.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene (4R)-limonene may increase the anticoagulant activities of Dabigatran etexilate. Investigational Abacavir The serum concentration of Abacavir can be decreased when it is combined with Dabigatran etexilate. Approved, Investigational Abciximab Dabigatran etexilate may increase the anticoagulant activities of Abciximab. Approved Abemaciclib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Abemaciclib. Approved, Investigational Aceclofenac Aceclofenac may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Acemetacin The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Dabigatran etexilate may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetaminophen The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Acetaminophen. Approved Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Dabigatran etexilate. Approved, Vet Approved Adapalene Adapalene may increase the anticoagulant activities of Dabigatran etexilate. Approved Afatinib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Afatinib. Approved Albendazole The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Albendazole. Approved, Vet Approved Alclofenac Alclofenac may increase the anticoagulant activities of Dabigatran etexilate. Approved, Withdrawn Aldosterone The serum concentration of Dabigatran etexilate can be decreased when it is combined with Aldosterone. Experimental, Investigational Alectinib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Alectinib. Approved, Investigational Alfentanil The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Alfentanil. Approved, Illicit Alfuzosin The serum concentration of Alfuzosin can be increased when it is combined with Dabigatran etexilate. Approved, Investigational Allylestrenol The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Allylestrenol. Approved Almasilate The serum concentration of Dabigatran etexilate can be decreased when it is combined with Almasilate. Approved, Experimental Alminoprofen Alminoprofen may increase the anticoagulant activities of Dabigatran etexilate. Experimental Aloglutamol The serum concentration of Dabigatran etexilate can be decreased when it is combined with Aloglutamol. Approved Aloxiprin Aloxiprin may increase the anticoagulant activities of Dabigatran etexilate. Experimental Alprazolam The serum concentration of Alprazolam can be increased when it is combined with Dabigatran etexilate. Approved, Illicit, Investigational Alprostadil Alprostadil may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Alteplase Alteplase may increase the anticoagulant activities of Dabigatran etexilate. Approved Altrenogest The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Altrenogest. Vet Approved Aluminium The serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminium. Approved, Investigational Aluminium acetoacetate The serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminium acetoacetate. Experimental Aluminium glycinate The serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminium glycinate. Experimental Aluminum hydroxide The serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminum hydroxide. Approved, Investigational Amantadine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amantadine. Approved Ambroxol acefyllinate The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Dabigatran etexilate. Experimental, Investigational Amineptine The serum concentration of Amineptine can be increased when it is combined with Dabigatran etexilate. Illicit, Withdrawn Aminohippuric acid The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Aminohippuric acid. Approved, Investigational Aminophylline The serum concentration of Aminophylline can be decreased when it is combined with Dabigatran etexilate. Approved Aminosalicylic Acid Aminosalicylic Acid may increase the anticoagulant activities of Dabigatran etexilate. Approved Amiodarone The serum concentration of Dabigatran etexilate can be increased when it is combined with Amiodarone. Approved, Investigational Amitriptyline The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amitriptyline. Approved Amitriptylinoxide The serum concentration of Amitriptylinoxide can be increased when it is combined with Dabigatran etexilate. Approved, Investigational Amlodipine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amlodipine. Approved Amoxapine The serum concentration of Amoxapine can be increased when it is combined with Dabigatran etexilate. Approved Amprenavir The serum concentration of Dabigatran etexilate can be decreased when it is combined with Amprenavir. Approved, Investigational Amsacrine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amsacrine. Approved, Investigational Anagrelide Anagrelide may increase the anticoagulant activities of Dabigatran etexilate. Approved Ancrod Dabigatran etexilate may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide Andrographolide may increase the anticoagulant activities of Dabigatran etexilate. Investigational Anisodamine Anisodamine may increase the anticoagulant activities of Dabigatran etexilate. Investigational Anistreplase Anistreplase may increase the anticoagulant activities of Dabigatran etexilate. Approved Antipyrine Antipyrine may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Antithrombin III human Dabigatran etexilate may increase the anticoagulant activities of Antithrombin III human. Approved Apalutamide The serum concentration of Dabigatran etexilate can be decreased when it is combined with Apalutamide. Approved, Investigational Apixaban Apixaban may increase the anticoagulant activities of Dabigatran etexilate. Approved Apocynin Apocynin may increase the anticoagulant activities of Dabigatran etexilate. Investigational Apremilast Apremilast may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Aprotinin The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Aprotinin. Approved, Investigational, Withdrawn Ardeparin Dabigatran etexilate may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Dabigatran etexilate may increase the anticoagulant activities of Argatroban. Approved, Investigational Astaxanthin Astaxanthin may increase the anticoagulant activities of Dabigatran etexilate. Investigational Astemizole The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Astemizole. Approved, Withdrawn Asunaprevir The serum concentration of Dabigatran etexilate can be increased when it is combined with Asunaprevir. Approved, Investigational, Withdrawn Atazanavir The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atazanavir. Approved, Investigational Atenolol The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atenolol. Approved Atorvastatin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atorvastatin. Approved Azapropazone Azapropazone may increase the anticoagulant activities of Dabigatran etexilate. Withdrawn Azelastine Azelastine may increase the anticoagulant activities of Dabigatran etexilate. Approved Azficel-T The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Azficel-T. Approved, Investigational Azithromycin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Azithromycin. Approved Balsalazide Balsalazide may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Batroxobin Batroxobin may increase the anticoagulant activities of Dabigatran etexilate. Experimental Bazedoxifene Bazedoxifene may decrease the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Becaplermin Dabigatran etexilate may increase the anticoagulant activities of Becaplermin. Approved, Investigational Bemiparin Bemiparin may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Bendazac Bendazac may increase the anticoagulant activities of Dabigatran etexilate. Experimental Benorilate Benorilate may increase the anticoagulant activities of Dabigatran etexilate. Experimental Benoxaprofen Benoxaprofen may increase the anticoagulant activities of Dabigatran etexilate. Withdrawn Benzocaine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Benzocaine. Approved, Investigational Benzydamine Benzydamine may increase the anticoagulant activities of Dabigatran etexilate. Approved Bepridil The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bepridil. Approved, Withdrawn Beraprost Beraprost may increase the anticoagulant activities of Dabigatran etexilate. Investigational Bevonium Bevonium may increase the anticoagulant activities of Dabigatran etexilate. Experimental Biperiden The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Biperiden. Approved, Investigational Bismuth subcitrate potassium The serum concentration of Dabigatran etexilate can be decreased when it is combined with Bismuth Subcitrate. Approved, Investigational Bismuth subnitrate The serum concentration of Dabigatran etexilate can be decreased when it is combined with Bismuth subnitrate. Approved Bivalirudin Dabigatran etexilate may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Boceprevir The serum concentration of Dabigatran etexilate can be decreased when it is combined with Boceprevir. Approved, Withdrawn Bosutinib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bosutinib. Approved Brinase Brinase may increase the anticoagulant activities of Dabigatran etexilate. Experimental Bromfenac Bromfenac may increase the anticoagulant activities of Dabigatran etexilate. Approved Bromocriptine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bromocriptine. Approved, Investigational Bucillamine Bucillamine may increase the anticoagulant activities of Dabigatran etexilate. Investigational Bufexamac Bufexamac may increase the anticoagulant activities of Dabigatran etexilate. Approved, Experimental Buflomedil Buflomedil may increase the anticoagulant activities of Dabigatran etexilate. Experimental Bumadizone Bumadizone may increase the anticoagulant activities of Dabigatran etexilate. Experimental Buprenorphine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Buspirone. Approved, Investigational Butriptyline The serum concentration of Butriptyline can be increased when it is combined with Dabigatran etexilate. Approved Butylphthalide Butylphthalide may increase the anticoagulant activities of Dabigatran etexilate. Investigational Cabazitaxel The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cabazitaxel. Approved Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Dabigatran etexilate. Approved Caffeine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Caffeine. Approved Calcium Carbonate The serum concentration of Dabigatran etexilate can be decreased when it is combined with Calcium Carbonate. Approved, Investigational Calcium silicate The serum concentration of Dabigatran etexilate can be decreased when it is combined with Calcium silicate. Experimental Canagliflozin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Canagliflozin. Approved Candesartan The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Candesartan. Experimental Candesartan cilexetil The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Candesartan cilexetil. Approved Cangrelor Cangrelor may increase the anticoagulant activities of Dabigatran etexilate. Approved Caplacizumab Caplacizumab may increase the anticoagulant activities of Dabigatran etexilate. Investigational Captopril The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Captopril. Approved Carbamazepine The serum concentration of Dabigatran etexilate can be decreased when it is combined with Carbamazepine. Approved, Investigational Carprofen Carprofen may increase the anticoagulant activities of Dabigatran etexilate. Approved, Vet Approved, Withdrawn Carvedilol The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Carvedilol. Approved, Investigational Caspofungin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Caspofungin. Approved Castanospermine Castanospermine may increase the anticoagulant activities of Dabigatran etexilate. Experimental Celecoxib Celecoxib may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Certoparin Dabigatran etexilate may increase the anticoagulant activities of Certoparin. Approved, Investigational Chlormadinone The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Chlormadinone. Experimental Chloroquine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chloroquine. Approved, Investigational, Vet Approved Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Dabigatran etexilate. Investigational, Withdrawn Chlorpromazine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorpromazine. Approved, Investigational, Vet Approved Chlorpropamide The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorpropamide. Approved, Investigational Chlorprothixene The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorprothixene. Approved, Investigational, Withdrawn Cholesterol The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cholesterol. Approved, Investigational Cholic Acid The serum concentration of Dabigatran etexilate can be decreased when it is combined with Cholic Acid. Approved Choline magnesium trisalicylate Choline magnesium trisalicylate may increase the anticoagulant activities of Dabigatran etexilate. Approved Cilazapril The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cilazapril. Approved Cilostazol Cilostazol may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Cimetidine The serum concentration of Dabigatran etexilate can be decreased when it is combined with Cimetidine. Approved, Investigational Ciprofloxacin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ciprofloxacin. Approved, Investigational Citalopram The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Citalopram. Approved Citric Acid Dabigatran etexilate may increase the anticoagulant activities of Citric Acid. Approved, Nutraceutical, Vet Approved Clarithromycin The serum concentration of Dabigatran etexilate can be increased when it is combined with Clarithromycin. Approved Clofazimine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Clofazimine. Approved, Investigational Clomipramine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Clomipramine. Approved, Investigational, Vet Approved Clonixin Clonixin may increase the anticoagulant activities of Dabigatran etexilate. Approved Clopidogrel Clopidogrel may increase the anticoagulant activities of Dabigatran etexilate. Approved Cloricromen Cloricromen may increase the anticoagulant activities of Dabigatran etexilate. Experimental Clorindione Clorindione may increase the anticoagulant activities of Dabigatran etexilate. Experimental Clotrimazole The serum concentration of Dabigatran etexilate can be decreased when it is combined with Clotrimazole. Approved, Vet Approved Cobicistat The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cobicistat. Approved Colchicine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Colchicine. Approved Colforsin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Colforsin. Experimental, Investigational Collagenase clostridium histolyticum The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Collagenase clostridium histolyticum. Approved, Investigational Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Dabigatran etexilate. Approved Crizotinib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Crizotinib. Approved Curcumin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Curcumin. Approved, Investigational Cyclophosphamide The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cyclophosphamide. Approved, Investigational Cyclosporine The serum concentration of Dabigatran etexilate can be decreased when it is combined with Cyclosporine. Approved, Investigational, Vet Approved Daclatasvir The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Daclatasvir. Approved, Investigational Dactinomycin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dactinomycin. Approved, Investigational Daidzein Daidzein may decrease the anticoagulant activities of Dabigatran etexilate. Experimental Dalteparin Dabigatran etexilate may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Dabigatran etexilate may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Dabigatran etexilate may increase the anticoagulant activities of Darexaban. Investigational Dasatinib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dasatinib. Approved, Investigational Daunorubicin The serum concentration of Dabigatran etexilate can be decreased when it is combined with Daunorubicin. Approved Deferasirox The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Deferasirox. Approved, Investigational Defibrotide Defibrotide may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Delavirdine The serum concentration of Delavirdine can be decreased when it is combined with Dabigatran etexilate. Approved Demegestone The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Demegestone. Approved Deoxycholic Acid The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Deoxycholic Acid. Approved Dersalazine Dersalazine may increase the anticoagulant activities of Dabigatran etexilate. Investigational Desipramine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desipramine. Approved, Investigational Desirudin Dabigatran etexilate may increase the anticoagulant activities of Desirudin. Approved Desloratadine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desloratadine. Approved, Investigational Desmoteplase Desmoteplase may increase the anticoagulant activities of Dabigatran etexilate. Investigational Desogestrel The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Desogestrel. Approved Dexamethasone The serum concentration of Dabigatran etexilate can be decreased when it is combined with Dexamethasone. Approved, Investigational, Vet Approved Dexlansoprazole The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Dexlansoprazole resulting in a loss in efficacy. Approved, Investigational Dexrabeprazole The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Dexrabeprazole resulting in a loss in efficacy. Experimental Dextran Dabigatran etexilate may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dextromethorphan The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dextromethorphan. Approved Dibenzepin The serum concentration of Dibenzepin can be increased when it is combined with Dabigatran etexilate. Experimental Diclofenac The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Diclofenac. Approved, Vet Approved Dicoumarol Dabigatran etexilate may increase the anticoagulant activities of Dicoumarol. Approved Dienestrol Dienestrol may decrease the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Dienogest The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Dienogest. Approved Diethylstilbestrol The serum concentration of Diethylstilbestrol can be decreased when it is combined with Dabigatran etexilate. Approved, Investigational Difenpiramide Difenpiramide may increase the anticoagulant activities of Dabigatran etexilate. Experimental Diflunisal Diflunisal may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Digoxin The serum concentration of Dabigatran etexilate can be decreased when it is combined with Digoxin. Approved Dihydroergotamine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dihydroergotamine. Approved, Investigational Diltiazem The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Diltiazem. Approved, Investigational Dimetacrine The serum concentration of Dimetacrine can be increased when it is combined with Dabigatran etexilate. Approved, Withdrawn Diphenadione Diphenadione may increase the anticoagulant activities of Dabigatran etexilate. Experimental Dipyridamole Dipyridamole may increase the anticoagulant activities of Dabigatran etexilate. Approved Ditazole Ditazole may increase the anticoagulant activities of Dabigatran etexilate. Approved, Withdrawn Dosulepin The serum concentration of Dosulepin can be increased when it is combined with Dabigatran etexilate. Approved Doxazosin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Doxazosin. Approved Doxepin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Doxepin. Approved, Investigational Doxorubicin The serum concentration of Dabigatran etexilate can be decreased when it is combined with Doxorubicin. Approved, Investigational Dronabinol The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dronabinol. Approved, Illicit Dronedarone The serum concentration of Dabigatran etexilate can be increased when it is combined with Dronedarone. Approved Drospirenone The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Drospirenone. Approved Drotrecogin alfa Drotrecogin alfa may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational, Withdrawn Droxicam Droxicam may increase the anticoagulant activities of Dabigatran etexilate. Withdrawn Duvelisib Duvelisib may increase the anticoagulant activities of Dabigatran etexilate. Investigational Dydrogesterone The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Dydrogesterone. Approved, Investigational, Withdrawn Dyphylline The serum concentration of Dyphylline can be decreased when it is combined with Dabigatran etexilate. Approved E-6201 E-6201 may increase the anticoagulant activities of Dabigatran etexilate. Investigational Edetic Acid Dabigatran etexilate may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Dabigatran etexilate may increase the anticoagulant activities of Edoxaban. Approved Enalapril The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enalapril. Approved, Vet Approved Enasidenib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enasidenib. Approved, Investigational Enfuvirtide The serum concentration of Enfuvirtide can be increased when it is combined with Dabigatran etexilate. Approved, Investigational Enoxaparin Dabigatran etexilate may increase the anticoagulant activities of Enoxaparin. Approved Enzalutamide The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enzalutamide. Approved Epimestrol Epimestrol may decrease the anticoagulant activities of Dabigatran etexilate. Experimental Epinastine Epinastine may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Epirizole Epirizole may increase the anticoagulant activities of Dabigatran etexilate. Approved Eplivanserin Eplivanserin may increase the anticoagulant activities of Dabigatran etexilate. Investigational eplivanserine eplivanserine may increase the anticoagulant activities of Dabigatran etexilate. Investigational Epoprostenol Epoprostenol may increase the anticoagulant activities of Dabigatran etexilate. Approved Eptifibatide Eptifibatide may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Equol Equol may decrease the anticoagulant activities of Dabigatran etexilate. Investigational Ergoloid mesylate The serum concentration of Ergoloid mesylate can be increased when it is combined with Dabigatran etexilate. Approved Ergonovine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ergonovine. Approved Ergotamine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ergotamine. Approved Erythromycin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Erythromycin. Approved, Investigational, Vet Approved Esomeprazole The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Esomeprazole resulting in a loss in efficacy. Approved, Investigational Estradiol The serum concentration of Estradiol can be decreased when it is combined with Dabigatran etexilate. Approved, Investigational, Vet Approved Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Dabigatran etexilate. Approved, Investigational, Vet Approved Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Dabigatran etexilate. Approved, Investigational, Vet Approved Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Dabigatran etexilate. Approved, Investigational, Vet Approved Estramustine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Estramustine. Approved, Investigational Estriol The serum concentration of Dabigatran etexilate can be decreased when it is combined with Estriol. Approved, Investigational, Vet Approved Estrogens, esterified Estrogens, esterified may decrease the anticoagulant activities of Dabigatran etexilate. Approved Estrone The serum concentration of Dabigatran etexilate can be decreased when it is combined with Estrone. Approved Etanercept Etanercept may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Ethenzamide Ethenzamide may increase the anticoagulant activities of Dabigatran etexilate. Experimental Ethinyl Estradiol The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Dabigatran etexilate. Approved Ethyl biscoumacetate Dabigatran etexilate may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Ethynodiol The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Ethynodiol. Experimental Etodolac Etodolac may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational, Vet Approved Etofenamate Etofenamate may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Etonogestrel The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Etonogestrel. Approved, Investigational Etoposide The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Etoposide. Approved Etoricoxib Etoricoxib may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Etravirine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Etravirine. Approved Evening primrose oil Evening primrose oil may increase the anticoagulant activities of Dabigatran etexilate. Investigational, Nutraceutical Exisulind Exisulind may increase the anticoagulant activities of Dabigatran etexilate. Investigational Felbinac Felbinac may increase the anticoagulant activities of Dabigatran etexilate. Experimental Felodipine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Felodipine. Approved, Investigational Fenbufen Fenbufen may increase the anticoagulant activities of Dabigatran etexilate. Approved Fenoprofen Fenoprofen may increase the anticoagulant activities of Dabigatran etexilate. Approved Fentanyl The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fentiazac Fentiazac may increase the anticoagulant activities of Dabigatran etexilate. Experimental Feprazone Feprazone may increase the anticoagulant activities of Dabigatran etexilate. Experimental Ferulic acid Dabigatran etexilate may increase the anticoagulant activities of Ferulic acid. Experimental Fexofenadine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fexofenadine. Approved, Investigational Fibrinolysin Fibrinolysin may increase the anticoagulant activities of Dabigatran etexilate. Investigational Fidaxomicin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fidaxomicin. Approved Floctafenine Floctafenine may increase the anticoagulant activities of Dabigatran etexilate. Approved, Withdrawn Fluconazole The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluconazole. Approved, Investigational Fluindione Dabigatran etexilate may increase the anticoagulant activities of Fluindione. Approved, Investigational Flunixin Flunixin may increase the anticoagulant activities of Dabigatran etexilate. Vet Approved Flunoxaprofen Flunoxaprofen may increase the anticoagulant activities of Dabigatran etexilate. Experimental Fluoxetine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluoxetine. Approved, Vet Approved Flupentixol The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Flupentixol. Approved, Investigational, Withdrawn Fluphenazine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluphenazine. Approved Flurazepam The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Flurazepam. Approved, Illicit, Investigational Flurbiprofen Flurbiprofen may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Fluvoxamine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluvoxamine. Approved, Investigational Fondaparinux Dabigatran etexilate may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Gabexate Dabigatran etexilate may increase the anticoagulant activities of Gabexate. Investigational Garlic The serum concentration of Dabigatran etexilate can be decreased when it is combined with Garlic. Approved, Nutraceutical Gefitinib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Gefitinib. Approved, Investigational Genistein The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Genistein. Investigational Gestodene The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Gestodene. Approved, Investigational Gestonorone The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Gestonorone. Experimental Gestrinone The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Gestrinone. Approved Glecaprevir The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Glecaprevir. Approved, Investigational Glyburide The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Glyburide. Approved Glycerin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Glycerin. Approved, Investigational Gramicidin D The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Gramicidin D. Approved Grepafloxacin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal Guacetisal may increase the anticoagulant activities of Dabigatran etexilate. Experimental Haloperidol The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Haloperidol. Approved Hemin Hemin may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Hemoglobin crosfumaril Hemoglobin crosfumaril may increase the anticoagulant activities of Dabigatran etexilate. Experimental Heparin Dabigatran etexilate may increase the anticoagulant activities of Heparin. Approved, Investigational Hexestrol Hexestrol may decrease the anticoagulant activities of Dabigatran etexilate. Withdrawn Higenamine Higenamine may increase the anticoagulant activities of Dabigatran etexilate. Investigational Hydrocortisone The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Hydrocortisone. Approved, Vet Approved Hydrotalcite The serum concentration of Dabigatran etexilate can be decreased when it is combined with Hydrotalcite. Approved, Experimental, Investigational Hydroxyprogesterone caproate The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Hydroxyprogesterone caproate. Approved, Investigational Hydroxytyrosol Hydroxytyrosol may increase the anticoagulant activities of Dabigatran etexilate. Investigational Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Ibritumomab tiuxetan. Approved, Investigational Ibrutinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Dabigatran etexilate. Approved Ibudilast Ibudilast may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Ibuprofen Ibuprofen may increase the anticoagulant activities of Dabigatran etexilate. Approved Ibuproxam Ibuproxam may increase the anticoagulant activities of Dabigatran etexilate. Withdrawn Icatibant Icatibant may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Icosapent ethyl Icosapent ethyl may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational, Nutraceutical Idelalisib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Idelalisib. Approved Idraparinux Dabigatran etexilate may increase the anticoagulant activities of Idraparinux. Investigational Ifenprodil Ifenprodil may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational, Withdrawn Ifetroban Ifetroban may increase the anticoagulant activities of Dabigatran etexilate. Investigational Iloprost Iloprost may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Imatinib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Imatinib. Approved Imidazole salicylate Imidazole salicylate may increase the anticoagulant activities of Dabigatran etexilate. Experimental Imipramine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Imipramine. Approved Indinavir The serum concentration of Dabigatran etexilate can be decreased when it is combined with Indinavir. Approved Indobufen Indobufen may increase the anticoagulant activities of Dabigatran etexilate. Investigational Indomethacin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Indomethacin. Approved, Investigational Indoprofen Indoprofen may increase the anticoagulant activities of Dabigatran etexilate. Withdrawn Iprindole The serum concentration of Iprindole can be increased when it is combined with Dabigatran etexilate. Experimental Isavuconazole The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Isavuconazole. Approved, Investigational Isavuconazonium The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Isavuconazonium. Approved, Investigational Isoxicam Isoxicam may increase the anticoagulant activities of Dabigatran etexilate. Withdrawn Itraconazole The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ivacaftor. Approved Ivermectin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ivermectin. Approved, Investigational, Vet Approved Kebuzone Kebuzone may increase the anticoagulant activities of Dabigatran etexilate. Experimental Ketamine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ketamine. Approved, Vet Approved Ketanserin Ketanserin may increase the anticoagulant activities of Dabigatran etexilate. Investigational Ketoconazole The serum concentration of Dabigatran etexilate can be increased when it is combined with Ketoconazole. Approved, Investigational Ketoprofen Ketoprofen may increase the anticoagulant activities of Dabigatran etexilate. Approved, Vet Approved Ketorolac Ketorolac may increase the anticoagulant activities of Dabigatran etexilate. Approved Lansoprazole The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lansoprazole. Approved, Investigational Lapatinib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lapatinib. Approved, Investigational Leflunomide Leflunomide may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Lepirudin Dabigatran etexilate may increase the anticoagulant activities of Lepirudin. Approved Letaxaban Dabigatran etexilate may increase the anticoagulant activities of Letaxaban. Investigational Letermovir The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Letermovir. Approved, Investigational Levofloxacin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Levofloxacin. Approved, Investigational Levonorgestrel The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Levonorgestrel. Approved, Investigational Levothyroxine The serum concentration of Dabigatran etexilate can be decreased when it is combined with Levothyroxine. Approved Lidocaine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lidocaine. Approved, Vet Approved Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Dabigatran etexilate. Approved, Investigational Linsidomine Linsidomine may increase the anticoagulant activities of Dabigatran etexilate. Experimental Liothyronine The serum concentration of Dabigatran etexilate can be decreased when it is combined with Liothyronine. Approved, Vet Approved Liotrix The serum concentration of Dabigatran etexilate can be decreased when it is combined with Liotrix. Approved Lisofylline Lisofylline may increase the anticoagulant activities of Dabigatran etexilate. Investigational Lofepramine The serum concentration of Lofepramine can be increased when it is combined with Dabigatran etexilate. Experimental Lomitapide The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lomitapide. Approved, Investigational Lonazolac Lonazolac may increase the anticoagulant activities of Dabigatran etexilate. Experimental Loperamide The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Loperamide. Approved Lopinavir The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lopinavir. Approved Loratadine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Loratadine. Approved, Investigational Lornoxicam Lornoxicam may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Losartan The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Losartan. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Dabigatran etexilate. Approved, Investigational Loxoprofen Loxoprofen may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Lumacaftor The serum concentration of Dabigatran etexilate can be decreased when it is combined with Lumacaftor. Approved Lumiracoxib Lumiracoxib may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Lynestrenol The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Lynestrenol. Approved, Investigational Magaldrate The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magaldrate. Approved, Withdrawn Magnesium carbonate The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium carbonate. Approved, Investigational Magnesium hydroxide The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium hydroxide. Approved, Investigational Magnesium oxide The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium oxide. Approved Magnesium peroxide The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium peroxide. Experimental Magnesium salicylate Magnesium salicylate may increase the anticoagulant activities of Dabigatran etexilate. Approved Magnesium silicate The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium silicate. Approved Magnesium Trisilicate The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium Trisilicate. Approved Maprotiline The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Maprotiline. Approved, Investigational Masoprocol Masoprocol may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Mebendazole The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mebendazole. Approved, Vet Approved Meclofenamic acid Meclofenamic acid may increase the anticoagulant activities of Dabigatran etexilate. Approved, Vet Approved Medrogestone The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medrogestone. Approved Medroxyprogesterone acetate The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medroxyprogesterone acetate. Approved, Investigational Mefenamic acid Mefenamic acid may increase the anticoagulant activities of Dabigatran etexilate. Approved Mefloquine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mefloquine. Approved, Investigational Megestrol acetate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Megestrol acetate. Approved, Investigational, Vet Approved Melagatran Dabigatran etexilate may increase the anticoagulant activities of Melagatran. Experimental Melitracen The serum concentration of Melitracen can be increased when it is combined with Dabigatran etexilate. Experimental, Investigational Meloxicam Meloxicam may increase the anticoagulant activities of Dabigatran etexilate. Approved, Vet Approved Meprobamate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Meprobamate. Approved, Illicit Mesalazine Mesalazine may increase the anticoagulant activities of Dabigatran etexilate. Approved Mestranol The serum concentration of Mestranol can be decreased when it is combined with Dabigatran etexilate. Approved Metamizole Metamizole may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational, Withdrawn Methadone The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Methadone. Approved Methallenestril Methallenestril may decrease the anticoagulant activities of Dabigatran etexilate. Experimental Methyl salicylate Methyl salicylate may increase the anticoagulant activities of Dabigatran etexilate. Approved, Vet Approved Methylergometrine The serum concentration of Methylergometrine can be increased when it is combined with Dabigatran etexilate. Approved Methylestrenolone The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Methylestrenolone. Experimental Metoprolol The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Metoprolol. Approved, Investigational Mibefradil The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mibefradil. Investigational, Withdrawn Miconazole The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Miconazole. Approved, Investigational, Vet Approved Midazolam The serum concentration of Dabigatran etexilate can be decreased when it is combined with Midazolam. Approved, Illicit Mifepristone The serum concentration of Dabigatran etexilate can be decreased when it is combined with Mifepristone. Approved, Investigational Milrinone Milrinone may increase the anticoagulant activities of Dabigatran etexilate. Approved Mitomycin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mitomycin. Approved Mitoxantrone The serum concentration of Dabigatran etexilate can be decreased when it is combined with Mitoxantrone. Approved, Investigational Mizoribine Mizoribine may increase the anticoagulant activities of Dabigatran etexilate. Investigational Mofebutazone Mofebutazone may increase the anticoagulant activities of Dabigatran etexilate. Experimental Morphine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Morphine. Approved, Investigational Moxestrol Moxestrol may decrease the anticoagulant activities of Dabigatran etexilate. Experimental Mycophenolate mofetil Mycophenolate mofetil may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Mycophenolic acid Mycophenolic acid may increase the anticoagulant activities of Dabigatran etexilate. Approved Nabumetone Nabumetone may increase the anticoagulant activities of Dabigatran etexilate. Approved Nadroparin Dabigatran etexilate may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Dabigatran etexilate may increase the anticoagulant activities of Nafamostat. Approved, Investigational Naftifine Naftifine may increase the anticoagulant activities of Dabigatran etexilate. Approved Naftopidil Naftopidil may increase the anticoagulant activities of Dabigatran etexilate. Investigational Naltrexone The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Naltrexone. Approved, Investigational, Vet Approved Naproxen Naproxen may increase the anticoagulant activities of Dabigatran etexilate. Approved, Vet Approved Naringenin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Naringenin. Experimental Nefazodone The serum concentration of Dabigatran etexilate can be decreased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Dabigatran etexilate can be decreased when it is combined with Nelfinavir. Approved Neostigmine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Neostigmine. Approved, Vet Approved Nepafenac Nepafenac may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Nicardipine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nicardipine. Approved, Investigational Nifedipine The serum concentration of Dabigatran etexilate can be decreased when it is combined with Nifedipine. Approved Nifenazone Nifenazone may increase the anticoagulant activities of Dabigatran etexilate. Experimental Niflumic Acid Niflumic Acid may increase the anticoagulant activities of Dabigatran etexilate. Approved Nilotinib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nilotinib. Approved, Investigational Nimesulide Nimesulide may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational, Withdrawn Nintedanib The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Nintedanib. Approved Nisoldipine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nisoldipine. Approved Nitrazepam The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrazepam. Approved Nitrendipine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrendipine. Approved, Investigational Nitroaspirin Nitroaspirin may increase the anticoagulant activities of Dabigatran etexilate. Investigational Nomegestrol The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Nomegestrol. Approved Norethisterone The serum concentration of Dabigatran etexilate can be decreased when it is combined with Norethisterone. Approved Norgestrienone The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Norgestrienone. Experimental Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Dabigatran etexilate. Approved Obinutuzumab The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Obinutuzumab. Approved, Investigational Olopatadine Olopatadine may increase the anticoagulant activities of Dabigatran etexilate. Approved Olsalazine Olsalazine may increase the anticoagulant activities of Dabigatran etexilate. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Omacetaxine mepesuccinate. Approved, Investigational Omega-3 fatty acids Omega-3 fatty acids may increase the anticoagulant activities of Dabigatran etexilate. Approved, Nutraceutical Omega-3-carboxylic acids The therapeutic efficacy of Dabigatran etexilate can be increased when used in combination with Omega-3-carboxylic acids. Approved, Investigational Omeprazole The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Omeprazole. Approved, Investigational, Vet Approved Opipramol The serum concentration of Opipramol can be increased when it is combined with Dabigatran etexilate. Investigational Orgotein Orgotein may increase the anticoagulant activities of Dabigatran etexilate. Vet Approved Otamixaban Dabigatran etexilate may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin Oxaprozin may increase the anticoagulant activities of Dabigatran etexilate. Approved Oxyphenbutazone Oxyphenbutazone may increase the anticoagulant activities of Dabigatran etexilate. Approved, Withdrawn Ozagrel Ozagrel may increase the anticoagulant activities of Dabigatran etexilate. Investigational P-Nitrophenol The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with P-Nitrophenol. Experimental Paclitaxel The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Paclitaxel. Approved, Vet Approved Palmidrol Palmidrol may increase the anticoagulant activities of Dabigatran etexilate. Experimental, Nutraceutical Palmitic Acid The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Palmitic Acid. Approved, Experimental Pantoprazole The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pantoprazole. Approved Parecoxib Parecoxib may increase the anticoagulant activities of Dabigatran etexilate. Approved Parnaparin Parnaparin may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Paroxetine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Paroxetine. Approved, Investigational Parthenolide Parthenolide may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Pentaerythritol Tetranitrate Dabigatran etexilate may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Dabigatran etexilate may increase the anticoagulant activities of Pentosan Polysulfate. Approved Pentoxifylline Pentoxifylline may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Perindopril The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Perindopril. Approved Pethidine The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Pethidine. Approved Phenindione Dabigatran etexilate may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenobarbital The serum concentration of Dabigatran etexilate can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenprocoumon Dabigatran etexilate may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenyl aminosalicylate Phenyl aminosalicylate may increase the anticoagulant activities of Dabigatran etexilate. Approved Phenylbutazone Phenylbutazone may increase the anticoagulant activities of Dabigatran etexilate. Approved, Vet Approved Pibrentasvir The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pibrentasvir. Approved, Investigational Picotamide Picotamide may increase the anticoagulant activities of Dabigatran etexilate. Experimental Pimecrolimus Pimecrolimus may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Pimozide The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pimozide. Approved Pirfenidone Pirfenidone may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Piroxicam Piroxicam may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Pirprofen Pirprofen may increase the anticoagulant activities of Dabigatran etexilate. Experimental Pitolisant The serum concentration of Dabigatran etexilate can be decreased when it is combined with Pitolisant. Approved, Investigational Platelet Activating Factor The serum concentration of Dabigatran etexilate can be decreased when it is combined with Platelet Activating Factor. Experimental Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Dabigatran etexilate. Approved Ponatinib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ponatinib. Approved, Investigational Posaconazole The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Posaconazole. Approved, Investigational, Vet Approved Potassium Citrate Dabigatran etexilate may increase the anticoagulant activities of Potassium Citrate. Approved, Investigational, Vet Approved Pranoprofen Pranoprofen may increase the anticoagulant activities of Dabigatran etexilate. Experimental, Investigational Prasugrel Prasugrel may increase the anticoagulant activities of Dabigatran etexilate. Approved Pravastatin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pravastatin. Approved Prazosin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Prazosin. Approved Prednisone The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Prednisone. Approved, Vet Approved Probenecid The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Probenecid. Approved, Investigational Progesterone The serum concentration of Dabigatran etexilate can be decreased when it is combined with Progesterone. Approved, Vet Approved Proglumetacin Proglumetacin may increase the anticoagulant activities of Dabigatran etexilate. Experimental Promegestone The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Promegestone. Experimental Promestriene Promestriene may decrease the anticoagulant activities of Dabigatran etexilate. Investigational Promethazine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Promethazine. Approved, Investigational Propacetamol Propacetamol may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Propafenone The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Propafenone. Approved Propranolol The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Propranolol. Approved, Investigational Propyphenazone Propyphenazone may increase the anticoagulant activities of Dabigatran etexilate. Experimental Proquazone Proquazone may increase the anticoagulant activities of Dabigatran etexilate. Experimental Protein C Dabigatran etexilate may increase the anticoagulant activities of Protein C. Approved Protein S human Dabigatran etexilate may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Dabigatran etexilate may increase the anticoagulant activities of Protocatechualdehyde. Approved Protriptyline The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Protriptyline. Approved PTC299 PTC299 may increase the anticoagulant activities of Dabigatran etexilate. Investigational Quercetin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Quercetin. Experimental, Investigational Quinacrine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Quinacrine. Approved, Investigational Quinestrol Quinestrol may decrease the anticoagulant activities of Dabigatran etexilate. Approved Quingestanol The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Quingestanol. Experimental Quinidine The serum concentration of Dabigatran etexilate can be increased when it is combined with Quinidine. Approved, Investigational Quinine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Quinine. Approved Rabeprazole The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Rabeprazole resulting in a loss in efficacy. Approved, Investigational Ramatroban Ramatroban may increase the anticoagulant activities of Dabigatran etexilate. Investigational Ranitidine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ranitidine. Approved Ranolazine The serum concentration of Dabigatran etexilate can be increased when it is combined with Ranolazine. Approved, Investigational Reboxetine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Reboxetine. Approved, Investigational Regorafenib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Regorafenib. Approved Relcovaptan Relcovaptan may increase the anticoagulant activities of Dabigatran etexilate. Investigational Reserpine The serum concentration of Dabigatran etexilate can be decreased when it is combined with Reserpine. Approved, Investigational Resveratrol Resveratrol may increase the anticoagulant activities of Dabigatran etexilate. Approved, Experimental, Investigational Reteplase Reteplase may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Reviparin Dabigatran etexilate may increase the anticoagulant activities of Reviparin. Approved, Investigational Ridogrel Ridogrel may increase the anticoagulant activities of Dabigatran etexilate. Approved Rifampicin The serum concentration of Dabigatran etexilate can be decreased when it is combined with Rifampicin. Approved Rilpivirine The serum concentration of Dabigatran etexilate can be increased when it is combined with Rilpivirine. Approved Riociguat The serum concentration of Riociguat can be increased when it is combined with Dabigatran etexilate. Approved Ritonavir The serum concentration of Dabigatran etexilate can be decreased when it is combined with Ritonavir. Approved, Investigational Rivaroxaban Dabigatran etexilate may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib Rofecoxib may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational, Withdrawn Rolapitant The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Rolapitant. Approved, Investigational Rosiglitazone Rosiglitazone may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Rucaparib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Rucaparib. Approved, Investigational Salicylamide Salicylamide may increase the anticoagulant activities of Dabigatran etexilate. Approved Salicylic acid Salicylic acid may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational, Vet Approved Salsalate Salsalate may increase the anticoagulant activities of Dabigatran etexilate. Approved Saquinavir The serum concentration of Dabigatran etexilate can be decreased when it is combined with Saquinavir. Approved, Investigational Sarpogrelate Sarpogrelate may increase the anticoagulant activities of Dabigatran etexilate. Investigational Saruplase Saruplase may increase the anticoagulant activities of Dabigatran etexilate. Experimental Scopolamine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Scopolamine. Approved, Investigational Secoisolariciresinol Secoisolariciresinol may decrease the anticoagulant activities of Dabigatran etexilate. Investigational Selegiline The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Selegiline. Approved, Investigational, Vet Approved Selexipag Selexipag may increase the anticoagulant activities of Dabigatran etexilate. Approved Semapimod Semapimod may increase the anticoagulant activities of Dabigatran etexilate. Investigational Seratrodast Seratrodast may increase the anticoagulant activities of Dabigatran etexilate. Approved Serrapeptase Serrapeptase may increase the anticoagulant activities of Dabigatran etexilate. Investigational Sertraline The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sertraline. Approved Sevoflurane Sevoflurane may increase the anticoagulant activities of Dabigatran etexilate. Approved, Vet Approved Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Dabigatran etexilate. Approved, Investigational Simeprevir The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Simeprevir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Dabigatran etexilate. Approved Sirolimus The serum concentration of Dabigatran etexilate can be decreased when it is combined with Sirolimus. Approved, Investigational Sodium bicarbonate The serum concentration of Dabigatran etexilate can be decreased when it is combined with Sodium bicarbonate. Approved Sodium Citrate Dabigatran etexilate may increase the anticoagulant activities of Sodium Citrate. Approved, Investigational Sorafenib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sorafenib. Approved, Investigational Spironolactone The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Spironolactone. Approved SRT501 SRT501 may increase the anticoagulant activities of Dabigatran etexilate. Investigational St. John's Wort The metabolism of Dabigatran etexilate can be increased when combined with St. John's Wort. Approved, Investigational, Nutraceutical Staurosporine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Staurosporine. Experimental Streptokinase Streptokinase may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Streptozocin The serum concentration of Dabigatran etexilate can be decreased when it is combined with Streptozocin. Approved, Investigational Sugammadex Sugammadex may increase the anticoagulant activities of Dabigatran etexilate. Approved Sulfasalazine Sulfasalazine may increase the anticoagulant activities of Dabigatran etexilate. Approved Sulfinpyrazone Sulfinpyrazone may increase the anticoagulant activities of Dabigatran etexilate. Approved Sulindac Sulindac may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Sulodexide Dabigatran etexilate may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sumatriptan The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sumatriptan. Approved, Investigational Sunitinib The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sunitinib. Approved, Investigational Suprofen Suprofen may increase the anticoagulant activities of Dabigatran etexilate. Approved, Withdrawn Suxibuzone Suxibuzone may increase the anticoagulant activities of Dabigatran etexilate. Experimental Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Dabigatran etexilate. Approved Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dabigatran etexilate. Approved Tacrine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Tacrine. Investigational, Withdrawn Tacrolimus The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tacrolimus. Approved, Investigational Tamoxifen The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tamoxifen. Approved Tarenflurbil Tarenflurbil may increase the anticoagulant activities of Dabigatran etexilate. Investigational Taurocholic Acid The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Taurocholic Acid. Experimental Telaprevir The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Telaprevir. Approved, Withdrawn Telmisartan The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Telmisartan. Approved, Investigational Temsirolimus The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Temsirolimus. Approved Tenecteplase Tenecteplase may increase the anticoagulant activities of Dabigatran etexilate. Approved Tenidap Tenidap may increase the anticoagulant activities of Dabigatran etexilate. Experimental Tenoxicam Tenoxicam may increase the anticoagulant activities of Dabigatran etexilate. Approved Tepoxalin Tepoxalin may increase the anticoagulant activities of Dabigatran etexilate. Vet Approved Terazosin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Terazosin. Approved Terfenadine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Terfenadine. Approved, Withdrawn Teriflunomide Teriflunomide may increase the anticoagulant activities of Dabigatran etexilate. Approved Tesmilifene The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tesmilifene. Investigational Testosterone The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Testosterone. Approved, Investigational Testosterone cypionate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Testosterone cypionate. Approved Testosterone enanthate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Testosterone enanthate. Approved Testosterone undecanoate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Testosterone undecanoate. Approved, Investigational Theophylline The serum concentration of Theophylline can be decreased when it is combined with Dabigatran etexilate. Approved Tianeptine The serum concentration of Tianeptine can be increased when it is combined with Dabigatran etexilate. Approved, Investigational Tiaprofenic acid Tiaprofenic acid may increase the anticoagulant activities of Dabigatran etexilate. Approved Tibolone Tibolone may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Ticagrelor Ticagrelor may increase the anticoagulant activities of Dabigatran etexilate. Approved Ticlopidine Ticlopidine may increase the anticoagulant activities of Dabigatran etexilate. Approved Tinoridine Tinoridine may increase the anticoagulant activities of Dabigatran etexilate. Investigational Tinzaparin Tinzaparin may increase the anticoagulant activities of Dabigatran etexilate. Approved Tioclomarol Tioclomarol may increase the anticoagulant activities of Dabigatran etexilate. Experimental Tipranavir The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tipranavir. Approved, Investigational Tirofiban Tirofiban may increase the anticoagulant activities of Dabigatran etexilate. Approved Tolfenamic Acid Tolfenamic Acid may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Tolmetin Tolmetin may increase the anticoagulant activities of Dabigatran etexilate. Approved Tolvaptan The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Tolvaptan. Approved Tositumomab The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Tositumomab. Approved, Investigational Tranilast Tranilast may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Trapidil Trapidil may increase the anticoagulant activities of Dabigatran etexilate. Approved Trazodone The serum concentration of Dabigatran etexilate can be decreased when it is combined with Trazodone. Approved, Investigational Treprostinil Treprostinil may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Triazolam The serum concentration of Triazolam can be increased when it is combined with Dabigatran etexilate. Approved, Investigational Tribenoside Tribenoside may increase the anticoagulant activities of Dabigatran etexilate. Experimental Trifluoperazine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Trifluoperazine. Approved, Investigational Triflupromazine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Triflupromazine. Approved, Vet Approved Triflusal Triflusal may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Trimethoprim The serum concentration of Dabigatran etexilate can be decreased when it is combined with Trimethoprim. Approved, Vet Approved Trimipramine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Trimipramine. Approved Triptolide Triptolide may increase the anticoagulant activities of Dabigatran etexilate. Investigational Trolamine salicylate Trolamine salicylate may increase the anticoagulant activities of Dabigatran etexilate. Approved Troleandomycin The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Troleandomycin. Approved Tromethamine The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tromethamine. Approved Troxerutin Dabigatran etexilate may increase the anticoagulant activities of Troxerutin. Investigational Urokinase Urokinase may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational, Withdrawn Valdecoxib Valdecoxib may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational, Withdrawn Valproic Acid The serum concentration of Valproic Acid can be decreased when it is combined with Dabigatran etexilate. Approved, Investigational Velpatasvir The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Velpatasvir. Approved, Investigational Vemurafenib The serum concentration of Dabigatran etexilate can be increased when it is combined with Vemurafenib. Approved Venlafaxine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Venlafaxine. Approved Verapamil The serum concentration of Dabigatran etexilate can be increased when it is combined with Verapamil. Approved Vinblastine The serum concentration of Dabigatran etexilate can be decreased when it is combined with Vinblastine. Approved Vincristine The serum concentration of Dabigatran etexilate can be decreased when it is combined with Vincristine. Approved, Investigational Vinorelbine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Vinorelbine. Approved, Investigational Vitamin E Vitamin E may increase the anticoagulant activities of Dabigatran etexilate. Approved, Nutraceutical, Vet Approved Voacamine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Voacamine. Approved, Investigational Vorapaxar The risk or severity of adverse effects can be increased when Vorapaxar is combined with Dabigatran etexilate. Approved Voxilaprevir The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Voxilaprevir. Approved, Investigational Warfarin Dabigatran etexilate may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Dabigatran etexilate may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen Zaltoprofen may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational Zeranol Zeranol may decrease the anticoagulant activities of Dabigatran etexilate. Vet Approved Zidovudine The serum concentration of Zidovudine can be decreased when it is combined with Dabigatran etexilate. Approved Zileuton Zileuton may increase the anticoagulant activities of Dabigatran etexilate. Approved, Investigational, Withdrawn Zimelidine The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Zimelidine. Withdrawn Zomepirac Zomepirac may increase the anticoagulant activities of Dabigatran etexilate. Withdrawn - Food Interactions
- St. John's Wort
References
- Synthesis Reference
Christian Filser, Wolfgang Dersch, Rainer Hamm, Arndt Hausherr, Gunter Koch, Ulrich Scholz, Georg Zerban, "METHOD FOR PRODUCING AN INTERMEDIATE PRODUCT OF DABIGATRAN ETEXILATE." U.S. Patent US20110118471, issued May 19, 2011.
US20110118471- General References
- Bauer KA: New oral anticoagulants in development: potential for improved safety profiles. Rev Neurol Dis. 2010;7(1):1-8. [PubMed:20410856]
- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. [PubMed:19717844]
- Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI: Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009 Jan;101(1):77-85. [PubMed:19132192]
- Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan;24(1):1-9. doi: 10.1016/j.arth.2008.01.132. Epub 2008 Apr 14. [PubMed:18534438]
- Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P: A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005 Jan;3(1):103-11. [PubMed:15634273]
- Di Nisio M, Middeldorp S, Buller HR: Direct thrombin inhibitors. N Engl J Med. 2005 Sep 8;353(10):1028-40. [PubMed:16148288]
- Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R: Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005 May;45(5):555-63. [PubMed:15831779]
- Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L: Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007 Nov 1;100(9):1419-26. Epub 2007 Aug 17. [PubMed:17950801]
- Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007 Nov;5(11):2178-85. [PubMed:17764540]
- Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 Sep 15;370(9591):949-56. [PubMed:17869635]
- Scaglione F: New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. [PubMed:23292752]
- External Links
- Human Metabolome Database
- HMDB0015641
- KEGG Drug
- D07144
- PubChem Compound
- 6445226
- PubChem Substance
- 99443249
- ChemSpider
- 4948999
- BindingDB
- 50432209
- ChEBI
- 70746
- ChEMBL
- CHEMBL539697
- PharmGKB
- PA165958369
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Dabigatran
- ATC Codes
- B01AE07 — Dabigatran etexilate
- AHFS Codes
- 20:12.04.12 — Direct Thrombin Inhibitors
- FDA label
- Download (431 KB)
- MSDS
- Download (99.2 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Capsule Oral 110 mg Capsule Oral 110 mg/1 Capsule Oral 150 mg/1 Capsule Oral 150 mg Capsule Oral 75 mg Capsule Oral 75 mg/1 - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US9034822 No 2011-01-20 2031-01-20 US US6087380 No 1998-02-18 2018-02-18 US US7932273 No 2005-09-07 2025-09-07 US US7866474 No 2007-08-31 2027-08-31 US US9925174 No 2003-06-14 2023-06-14 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 180 +/- 3 (DSC: 10 K min^-1 heating rate) Not Available water solubility 1.8mg/ml, partly soluble MSDS logP 3.8 Not Available - Predicted Properties
Property Value Source Water Solubility 0.00466 mg/mL ALOGPS logP 5.17 ALOGPS logP 4.59 ChemAxon logS -5.1 ALOGPS pKa (Strongest Acidic) 17.89 ChemAxon pKa (Strongest Basic) 3.87 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 8 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 154.03 Å2 ChemAxon Rotatable Bond Count 17 ChemAxon Refractivity 176.43 m3·mol-1 ChemAxon Polarizability 71.11 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.942 Blood Brain Barrier + 0.8673 Caco-2 permeable - 0.7014 P-glycoprotein substrate Substrate 0.7412 P-glycoprotein inhibitor I Inhibitor 0.7539 P-glycoprotein inhibitor II Inhibitor 0.8443 Renal organic cation transporter Non-inhibitor 0.701 CYP450 2C9 substrate Non-substrate 0.858 CYP450 2D6 substrate Non-substrate 0.837 CYP450 3A4 substrate Substrate 0.6154 CYP450 1A2 substrate Non-inhibitor 0.6906 CYP450 2C9 inhibitor Non-inhibitor 0.5102 CYP450 2D6 inhibitor Non-inhibitor 0.8417 CYP450 2C19 inhibitor Inhibitor 0.5157 CYP450 3A4 inhibitor Inhibitor 0.781 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.5789 Ames test Non AMES toxic 0.6292 Carcinogenicity Non-carcinogens 0.8065 Biodegradation Not ready biodegradable 0.9931 Rat acute toxicity 2.7093 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9047 hERG inhibition (predictor II) Inhibitor 0.6181
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-00kk-0981100000-78856b63936cf67ebce2 MS/MS Spectrum - , positive LC-MS/MS splash10-004r-0292116000-55b368cbe92da888e681
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzimidazoles
- Sub Class
- Not Available
- Direct Parent
- Benzimidazoles
- Alternative Parents
- Phenylalkylamines / Aniline and substituted anilines / Secondary alkylarylamines / Pyridines and derivatives / N-substituted imidazoles / Imidolactams / Tertiary carboxylic acid amides / Heteroaromatic compounds / Amino acids and derivatives / Carboxylic acid esters show 10 more
- Substituents
- Benzimidazole / Aniline or substituted anilines / Phenylalkylamine / Secondary aliphatic/aromatic amine / Aralkylamine / Monocyclic benzene moiety / N-substituted imidazole / Pyridine / Benzenoid / Imidolactam show 27 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- carboxylic ester, carboxamidine, beta-alanine derivative, pyridines, aromatic amide, benzimidazoles (CHEBI:70746)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Thrombospondin receptor activity
- Specific Function
- Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostas...
- Gene Name
- F2
- Uniprot ID
- P00734
- Uniprot Name
- Prothrombin
- Molecular Weight
- 70036.295 Da
References
- Squizzato A, Dentali F, Steidl L, Ageno W: New direct thrombin inhibitors. Intern Emerg Med. 2009 Dec;4(6):479-84. doi: 10.1007/s11739-009-0314-8. Epub 2009 Sep 15. [PubMed:19756950]
- Liesenfeld KH, Schafer HG, Troconiz IF, Tillmann C, Eriksson BI, Stangier J: Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006 Nov;62(5):527-37. [PubMed:17061960]
- Karthikeyan G, Eikelboom JW, Hirsh J: Dabigatran: ready for prime time? Pol Arch Med Wewn. 2010 Apr;120(4):137-42. [PubMed:20424539]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Triglyceride lipase activity
- Specific Function
- Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
- Gene Name
- CES1
- Uniprot ID
- P23141
- Uniprot Name
- Liver carboxylesterase 1
- Molecular Weight
- 62520.62 Da
References
- Hu ZY, Parker RB, Herring VL, Laizure SC: Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704. doi: 10.1007/s00216-012-6576-4. Epub 2012 Dec 14. [PubMed:23239178]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Methylumbelliferyl-acetate deacetylase activity
- Specific Function
- Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows high catalytic efficiency for hydrolysis of cocaine, 4-methylumbelliferyl acetate, heroin and ...
- Gene Name
- CES2
- Uniprot ID
- O00748
- Uniprot Name
- Cocaine esterase
- Molecular Weight
- 61806.41 Da
References
- Hu ZY, Parker RB, Herring VL, Laizure SC: Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704. doi: 10.1007/s00216-012-6576-4. Epub 2012 Dec 14. [PubMed:23239178]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Retinoic acid binding
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
- Gene Name
- UGT1A9
- Uniprot ID
- O60656
- Uniprot Name
- UDP-glucuronosyltransferase 1-9
- Molecular Weight
- 59940.495 Da
References
- Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Glucuronosyltransferase activity
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
- Gene Name
- UGT2B7
- Uniprot ID
- P16662
- Uniprot Name
- UDP-glucuronosyltransferase 2B7
- Molecular Weight
- 60694.12 Da
References
- Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Glucuronosyltransferase activity
- Specific Function
- UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme displays activity toward several classes of xeno...
- Gene Name
- UGT2B15
- Uniprot ID
- P54855
- Uniprot Name
- UDP-glucuronosyltransferase 2B15
- Molecular Weight
- 61035.815 Da
References
- Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Nadph dehydrogenase (quinone) activity
- Specific Function
- The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vi...
- Gene Name
- NQO2
- Uniprot ID
- P16083
- Uniprot Name
- Ribosyldihydronicotinamide dehydrogenase [quinone]
- Molecular Weight
- 25918.4 Da
References
- Michaelis S, Marais A, Schrey AK, Graebner OY, Schaudt C, Sefkow M, Kroll F, Dreger M, Glinski M, Koester H, Metternich R, Fischer JJ: Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2). J Med Chem. 2012 Apr 26;55(8):3934-44. doi: 10.1021/jm3001339. Epub 2012 Apr 17. [PubMed:22494098]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Galanis T, Thomson L, Palladino M, Merli GJ: New oral anticoagulants. J Thromb Thrombolysis. 2011 Apr;31(3):310-20. doi: 10.1007/s11239-011-0559-8. [PubMed:21327511]
- Scaglione F: New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. [PubMed:23292752]
Drug created on May 03, 2010 12:25 / Updated on July 13, 2018 01:10